Alpha Tau to Participate in May Investor Conferences
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced its CFO Raphi Levy's participation in two upcoming investor conferences in May 2025. Levy will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, from 3:30-4:00 PM ET in New York. Additionally, he will attend the Lytham Partners Spring 2025 Investor Conference virtually on May 29, 2025, for one-on-one meetings. Investors can schedule meetings with Mr. Levy at both conferences through their respective H.C. Wainwright and Lytham Partners representatives.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore della terapia contro il cancro Alpha DaRT®, ha annunciato la partecipazione del suo CFO Raphi Levy a due conferenze per investitori previste per maggio 2025. Levy prenderà parte a un dialogo informale (fireside chat) durante la 3ª Conferenza Annuale BioConnect per Investitori di H.C. Wainwright il 20 maggio 2025, dalle 15:30 alle 16:00 ET a New York. Inoltre, parteciperà virtualmente al Conferenza per Investitori Primavera 2025 di Lytham Partners il 29 maggio 2025, per incontri individuali. Gli investitori possono prenotare appuntamenti con il Sig. Levy in entrambe le conferenze tramite i rispettivi rappresentanti di H.C. Wainwright e Lytham Partners.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la terapia contra el cáncer Alpha DaRT®, anunció la participación de su CFO Raphi Levy en dos próximas conferencias para inversores en mayo de 2025. Levy participará en una charla informal (fireside chat) en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright el 20 de mayo de 2025, de 3:30 a 4:00 PM ET en Nueva York. Además, asistirá virtualmente a la Conferencia de Inversores de Primavera 2025 de Lytham Partners el 29 de mayo de 2025, para reuniones individuales. Los inversores pueden programar reuniones con el Sr. Levy en ambas conferencias a través de sus respectivos representantes de H.C. Wainwright y Lytham Partners.
Alpha Tau Medical (NASDAQ: DRTS), 알파 다트(Alpha DaRT®) 암 치료제 개발사는 2025년 5월에 예정된 두 건의 투자자 컨퍼런스에 CFO 라피 레비(Raphi Levy)가 참석한다고 발표했습니다. 레비는 2025년 5월 20일 뉴욕에서 오후 3시 30분부터 4시까지 진행되는 H.C. 웨인라이트 제3회 연례 BioConnect 투자자 컨퍼런스의 화롯가 대화(fireside chat)에 참여할 예정입니다. 또한, 2025년 5월 29일에는 Lytham Partners 2025년 봄 투자자 컨퍼런스에 온라인으로 참석하여 1:1 미팅을 가질 예정입니다. 투자자들은 두 컨퍼런스 모두에서 H.C. 웨인라이트 및 Lytham Partners 담당자를 통해 레비 씨와 미팅을 예약할 수 있습니다.
Alpha Tau Medical (NASDAQ : DRTS), développeur de la thérapie contre le cancer Alpha DaRT®, a annoncé la participation de son directeur financier Raphi Levy à deux conférences investisseurs prévues en mai 2025. Levy participera à une discussion informelle (fireside chat) lors de la 3e conférence annuelle BioConnect pour investisseurs organisée par H.C. Wainwright le 20 mai 2025, de 15h30 à 16h00 ET à New York. De plus, il assistera virtuellement à la conférence investisseurs printemps 2025 de Lytham Partners le 29 mai 2025, pour des rendez-vous individuels. Les investisseurs peuvent prendre rendez-vous avec M. Levy lors des deux conférences via les représentants respectifs de H.C. Wainwright et Lytham Partners.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der Alpha DaRT®-Krebstherapie, gab bekannt, dass sein CFO Raphi Levy im Mai 2025 an zwei bevorstehenden Investorenkonferenzen teilnehmen wird. Levy wird an einem Fireside Chat auf der 3. jährlichen H.C. Wainwright BioConnect Investorenkonferenz am 20. Mai 2025 von 15:30 bis 16:00 Uhr ET in New York teilnehmen. Außerdem wird er am 29. Mai 2025 virtuell an der Lytham Partners Frühjahrs-Investorenkonferenz 2025 für Einzelgespräche teilnehmen. Investoren können Meetings mit Herrn Levy auf beiden Konferenzen über die jeweiligen Vertreter von H.C. Wainwright und Lytham Partners vereinbaren.
- None.
- None.
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
| Event: | H.C. Wainwright 3rd Annual BioConnect Investor Conference |
| Format: | Fireside Chat |
| Date: | May 20, 2025 |
| Time: | 3:30 – 4:00PM ET |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2025 Investor Conference |
| Format: | 1x1 Meetings |
| Date: | May 29, 2025 |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
FAQ
What investor conferences will Alpha Tau Medical (DRTS) attend in May 2025?
Who will represent Alpha Tau Medical (DRTS) at the May 2025 investor conferences?
What is Alpha Tau Medical's (DRTS) main product?
How can investors schedule meetings with Alpha Tau Medical (DRTS) at the May 2025 conferences?
